Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Holdings Increased by Handelsbanken Fonder AB

Handelsbanken Fonder AB boosted its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 7.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 21,600 shares of the biotechnology company’s stock after purchasing an additional 1,500 shares during the period. Handelsbanken Fonder AB’s holdings in Arrowhead Pharmaceuticals were worth $661,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in ARWR. Strs Ohio boosted its stake in shares of Arrowhead Pharmaceuticals by 7.1% during the 4th quarter. Strs Ohio now owns 28,500 shares of the biotechnology company’s stock worth $872,000 after acquiring an additional 1,900 shares in the last quarter. Louisiana State Employees Retirement System purchased a new position in Arrowhead Pharmaceuticals in the 4th quarter worth about $921,000. WCM Investment Management LLC raised its holdings in Arrowhead Pharmaceuticals by 13.6% during the 4th quarter. WCM Investment Management LLC now owns 172,865 shares of the biotechnology company’s stock worth $5,359,000 after buying an additional 20,635 shares during the period. Friedenthal Financial purchased a new stake in Arrowhead Pharmaceuticals during the fourth quarter valued at about $51,000. Finally, International Assets Investment Management LLC acquired a new position in shares of Arrowhead Pharmaceuticals in the fourth quarter worth about $443,000. 62.61% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on ARWR. Royal Bank of Canada restated an “outperform” rating and set a $50.00 price target on shares of Arrowhead Pharmaceuticals in a report on Wednesday, February 7th. HC Wainwright reiterated a “buy” rating and set a $90.00 price target on shares of Arrowhead Pharmaceuticals in a report on Thursday, February 8th. Bank of America lifted their target price on Arrowhead Pharmaceuticals from $29.00 to $37.00 and gave the company a “buy” rating in a research note on Tuesday, January 2nd. Citigroup increased their price target on shares of Arrowhead Pharmaceuticals from $33.00 to $34.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 7th. Finally, Morgan Stanley boosted their price objective on shares of Arrowhead Pharmaceuticals from $34.00 to $36.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 7th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $50.80.

Arrowhead Pharmaceuticals Stock Up 4.6 %

ARWR stock opened at $23.13 on Tuesday. The company has a market capitalization of $2.87 billion, a price-to-earnings ratio of -8.32 and a beta of 0.71. The firm has a 50 day moving average of $27.85 and a two-hundred day moving average of $28.83. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $20.67 and a 12 month high of $42.48.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its earnings results on Tuesday, February 6th. The biotechnology company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($0.78) by ($0.46). The business had revenue of $3.55 million for the quarter, compared to analyst estimates of $35.60 million. Arrowhead Pharmaceuticals had a negative return on equity of 90.77% and a negative net margin of 163.32%. The company’s quarterly revenue was down 94.3% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.39) earnings per share. On average, research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.7 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Hongbo Lu purchased 1,000 shares of the stock in a transaction on Wednesday, March 20th. The shares were bought at an average price of $27.50 per share, for a total transaction of $27,500.00. Following the completion of the acquisition, the director now directly owns 33,680 shares in the company, valued at approximately $926,200. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, CEO Christopher Richard Anzalone sold 57,499 shares of the stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $32.35, for a total transaction of $1,860,092.65. Following the completion of the sale, the chief executive officer now owns 3,715,048 shares in the company, valued at approximately $120,181,802.80. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Hongbo Lu purchased 1,000 shares of the company’s stock in a transaction on Wednesday, March 20th. The stock was acquired at an average cost of $27.50 per share, for a total transaction of $27,500.00. Following the completion of the transaction, the director now owns 33,680 shares in the company, valued at $926,200. The disclosure for this purchase can be found here. Corporate insiders own 4.50% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.